Amino acid derived prodrugs of propofol, compositions and uses thereof
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
1. A compound of Formula (I) is provided:
or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof, wherein:
R 1 is selected from the group consisting of hydrogen, (R 5 NH(CHR 4 ) p C(O))—, R 6 —, R 6 C(O)— and R 6 OC(O)—;
R 2 is —OR 7 or —(NR 8 (CHR 9 ) q C(O)OR 7 );
p and q are independently 1 or 2;
each R 4 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl, or optionally, when R 4 and R 5 are attached to adjacent atoms then R 4 and R 5 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R 5 is selected from the group consisting of hydrogen, R 6 —, R 6 C(O)—and R 6 OC(O)—;
R 6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, heteroaryl, substituted heteroaryl and heteroarylalkyl;
R 7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, heteroaryl, substituted heteroaryl and heteroarylalkyl;
R 8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, heteroaryl, substituted heteroaryl and heteroarylalkyl; and
each R 9 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl, or optionally, when R 8 and R 9 are attached to adjacent atoms then R 8 and R 9 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
with the proviso that when R 2 is —(NR 8 (CHR 9 ) q C(O)OR 7 ) then R 1 is not (R 5 NH(CHR 4 ) p C(O))—.
2. The compound of claim 1 having structural Formula (II):
or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof, wherein R 4 is hydrogen, alkanyl, substituted alkanyl, aryl, substituted aryl, arylalkanyl, substituted arylalkanyl, cycloalkanyl, heteroarylalkanyl or substituted heteroarylalkanyl.
3. The compound of claim 2 , wherein R 4 is selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, t-butyl, cyclopentyl, cyclohexyl, —CH 2 OH, —CH(OH)CH 3 , —CH 2 CO 2 H, —CH 2 CH 2 CO 2 H, —CH 2 CONH 2 , —CH 2 CH 2 NH 2 , —CH 2 CH 2 SCH 3 , —CH 2 SH, —CH 2 (CH 2 ) 3 NH 2 , —CH 2 CH 2 CH 2 NHC(NH)NH 2 , phenyl, benzyl, 4-hydroxybenzyl, 4-imidazolylmethyl and 3-indolylmethyl.
4. The compound of claim 3 , wherein the α-carbon of the N-terminal amino acid residue is of the L-configuration.
5. The compound of claim 3 , wherein the α-carbon of the N-terminal amino acid residue is of the D-configuration.
6. The compound of claim 3 , wherein the α-carbon of the C-terminal amino acid residue is of the L-configuration.
7. The compound of claim 3 , wherein the α-carbon of the C-terminal amino acid residue is of the D-configuration.
8. The compound of claim 1 having structural Formula (III):
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
9. The compound of claim 8 , wherein the α-carbon of the amino acid is of the L-configuration.
10. The compound of claim 8 , wherein the α-carbon of the amino acid is of the D-configuration.
11. A method for treating migraine, nausea, vomiting, anxiety, seizures, convulsions, trauma of the central nervous system, and neurodegenerative conditions selected from the group consisting of Friedrich's disease, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Pick disease in a patient, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 .
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable vehicle.
13. The composition of claim 12 for treatment of nausea and vomiting, comprising a 5-HT 3 antagonist.
14. The composition of claim 13 , wherein the 5-HT 3 antagonist is selected from the group consisting of ondansetron, granisetron, dolasetron, and palonosetron.
15. The composition of claim 12 for treatment of nausea and vomiting, comprising a corticosteroid.
16. The composition of claim 15 , wherein the corticosteroid comprises dexamethasone.
17. The method of claim 11 for treatment of nausea and vomiting, comprising administering a 5-HT 3 antagonist.
18. The method of claim 17 , wherein the 5-HT 3 antagonist is selected from the group consisting of ondansetron, granisetron, dolasetron, and palonosetron.
19. The method of claim 11 for treatment of nausea and vomiting, comprising administering a corticosteroid.
20. The method of claim 19 , wherein the corticosteroid comprises dexamethasone.